vs

Side-by-side financial comparison of Ultragenyx Pharmaceutical Inc. (RARE) and TOOTSIE ROLL INDUSTRIES INC (TR). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $196.3M, roughly 1.1× TOOTSIE ROLL INDUSTRIES INC). TOOTSIE ROLL INDUSTRIES INC runs the higher net margin — 14.7% vs -62.0%, a 76.7% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 1.5%). TOOTSIE ROLL INDUSTRIES INC produced more free cash flow last quarter ($61.0M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 13.2%).

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.

RARE vs TR — Head-to-Head

Bigger by revenue
RARE
RARE
1.1× larger
RARE
$207.3M
$196.3M
TR
Growing faster (revenue YoY)
RARE
RARE
+24.4% gap
RARE
25.9%
1.5%
TR
Higher net margin
TR
TR
76.7% more per $
TR
14.7%
-62.0%
RARE
More free cash flow
TR
TR
$161.7M more FCF
TR
$61.0M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
13.2%
TR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RARE
RARE
TR
TR
Revenue
$207.3M
$196.3M
Net Profit
$-128.6M
$28.8M
Gross Margin
35.7%
Operating Margin
-54.7%
17.0%
Net Margin
-62.0%
14.7%
Revenue YoY
25.9%
1.5%
Net Profit YoY
3.5%
27.9%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RARE
RARE
TR
TR
Q4 25
$207.3M
$196.3M
Q3 25
$159.9M
$232.7M
Q2 25
$166.5M
$155.1M
Q1 25
$139.3M
$148.5M
Q4 24
$164.6M
$193.4M
Q3 24
$139.5M
$225.9M
Q2 24
$147.0M
$150.7M
Q1 24
$108.8M
$153.2M
Net Profit
RARE
RARE
TR
TR
Q4 25
$-128.6M
$28.8M
Q3 25
$-180.4M
$35.7M
Q2 25
$-115.0M
$17.5M
Q1 25
$-151.1M
$18.1M
Q4 24
$-133.2M
$22.5M
Q3 24
$-133.5M
$32.8M
Q2 24
$-131.6M
$15.6M
Q1 24
$-170.7M
$15.8M
Gross Margin
RARE
RARE
TR
TR
Q4 25
35.7%
Q3 25
34.1%
Q2 25
36.4%
Q1 25
35.3%
Q4 24
39.1%
Q3 24
34.1%
Q2 24
33.5%
Q1 24
32.7%
Operating Margin
RARE
RARE
TR
TR
Q4 25
-54.7%
17.0%
Q3 25
-106.9%
13.9%
Q2 25
-64.8%
7.8%
Q1 25
-102.6%
15.5%
Q4 24
-74.3%
20.0%
Q3 24
-94.6%
15.6%
Q2 24
-79.1%
10.2%
Q1 24
-151.9%
7.3%
Net Margin
RARE
RARE
TR
TR
Q4 25
-62.0%
14.7%
Q3 25
-112.8%
15.3%
Q2 25
-69.0%
11.3%
Q1 25
-108.5%
12.2%
Q4 24
-80.9%
11.6%
Q3 24
-95.7%
14.5%
Q2 24
-89.5%
10.4%
Q1 24
-156.8%
10.3%
EPS (diluted)
RARE
RARE
TR
TR
Q4 25
$-1.28
Q3 25
$-1.81
Q2 25
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$-1.40
Q2 24
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RARE
RARE
TR
TR
Cash + ST InvestmentsLiquidity on hand
$421.0M
$176.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$-80.0M
$941.0M
Total Assets
$1.5B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RARE
RARE
TR
TR
Q4 25
$421.0M
$176.6M
Q3 25
$202.5M
$119.8M
Q2 25
$176.3M
$170.5M
Q1 25
$127.1M
$176.6M
Q4 24
$174.0M
$194.6M
Q3 24
$150.6M
$163.2M
Q2 24
$480.7M
$131.2M
Q1 24
$112.3M
$159.4M
Stockholders' Equity
RARE
RARE
TR
TR
Q4 25
$-80.0M
$941.0M
Q3 25
$9.2M
$918.9M
Q2 25
$151.3M
$893.1M
Q1 25
$144.2M
$879.4M
Q4 24
$255.0M
$870.7M
Q3 24
$346.8M
$870.2M
Q2 24
$432.4M
$841.4M
Q1 24
$140.3M
$834.4M
Total Assets
RARE
RARE
TR
TR
Q4 25
$1.5B
$1.3B
Q3 25
$1.2B
$1.2B
Q2 25
$1.3B
$1.2B
Q1 25
$1.3B
$1.1B
Q4 24
$1.5B
$1.1B
Q3 24
$1.5B
$1.1B
Q2 24
$1.6B
$1.1B
Q1 24
$1.3B
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RARE
RARE
TR
TR
Operating Cash FlowLast quarter
$-99.8M
$73.3M
Free Cash FlowOCF − Capex
$-100.8M
$61.0M
FCF MarginFCF / Revenue
-48.6%
31.1%
Capex IntensityCapex / Revenue
0.5%
6.3%
Cash ConversionOCF / Net Profit
2.55×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M
$96.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RARE
RARE
TR
TR
Q4 25
$-99.8M
$73.3M
Q3 25
$-91.4M
$62.2M
Q2 25
$-108.3M
$-8.5M
Q1 25
$-166.5M
$3.6M
Q4 24
$-79.3M
$68.8M
Q3 24
$-67.0M
$61.3M
Q2 24
$-77.0M
$-12.6M
Q1 24
$-190.7M
$21.4M
Free Cash Flow
RARE
RARE
TR
TR
Q4 25
$-100.8M
$61.0M
Q3 25
$-92.7M
$50.7M
Q2 25
$-110.7M
$-16.0M
Q1 25
$-167.8M
$750.0K
Q4 24
$-79.5M
$64.7M
Q3 24
$-68.6M
$55.8M
Q2 24
$-79.0M
$-16.6M
Q1 24
$-193.9M
$16.9M
FCF Margin
RARE
RARE
TR
TR
Q4 25
-48.6%
31.1%
Q3 25
-58.0%
21.8%
Q2 25
-66.5%
-10.3%
Q1 25
-120.5%
0.5%
Q4 24
-48.3%
33.5%
Q3 24
-49.2%
24.7%
Q2 24
-53.7%
-11.0%
Q1 24
-178.2%
11.0%
Capex Intensity
RARE
RARE
TR
TR
Q4 25
0.5%
6.3%
Q3 25
0.8%
5.0%
Q2 25
1.5%
4.8%
Q1 25
1.0%
1.9%
Q4 24
0.1%
2.1%
Q3 24
1.2%
2.4%
Q2 24
1.4%
2.6%
Q1 24
3.0%
2.9%
Cash Conversion
RARE
RARE
TR
TR
Q4 25
2.55×
Q3 25
1.74×
Q2 25
-0.49×
Q1 25
0.20×
Q4 24
3.06×
Q3 24
1.87×
Q2 24
-0.81×
Q1 24
1.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

TR
TR

Products$194.3M99%
Rental And Royalty$1.9M1%

Related Comparisons